(Clarity Pharmaceuticals: Eveleigh, Australia) -- Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, has signed a large-scale manufacturing supply agreement for copper-64 with Theragenics.

The agreement relates to Theragenics’ 134,000 sq ft production facility with a fleet of 14 cyclotrons close to Atlanta, a major U.S. transport hub, for centralized, large-scale copper-64 (Cu-64 or 64Cu) production ahead of anticipated 64Cu-SAR-bisPSMA commercial launch upon successful completion of Clarity’s Phase III registrational trials with this product, AMPLIFY¹ and CLARIFY², as well as subsequent U.S. Food and Drug Administration (FDA) New Drug Application (NDA) approval.

 …